Akeso, Summit’s ivonescimab extends lives in Keytruda head-to-head trial. What now?

About two years ago, a head-to-head progression-free survival win made Akeso and Summit’s ivonescimab—and the PD-1xVEGF class—the most promising agent to replace Keytruda. Now, that same trial has met its overall survival endpoint, but to a far more measured reception.